Eric Bjerkholt Sells 5,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer owned 42,181 shares in the company, valued at approximately $5,156,627.25. This represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.82, for a total value of $469,100.00.

Mirum Pharmaceuticals Trading Down 0.7%

Shares of MIRM stock opened at $127.70 on Friday. The business has a 50-day moving average of $105.93 and a 200 day moving average of $97.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $130.00. The stock has a market capitalization of $7.79 billion, a PE ratio of -9.38 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. During the same period last year, the firm earned ($0.30) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Raymond James Financial restated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, TD Cowen upped their price objective on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $143.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MIRM. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals in the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals in the fourth quarter worth about $32,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth about $33,000. Finally, Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.